How to access Veozah from Oman, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24
A Oman woman experiencing moderate-to-severe vasomotor symptoms (hot flashes, night sweats) associated with menopause may receive a prescription for Veozah (fezolinetant) from her treating gynaecologist, endocrinologist, or primary-care physician when hormone therapy is not appropriate or not preferred. Veozah is FDA-approved in the United States as the first non-hormonal neurokinin-3 receptor (NK3R) antagonist for this indication. Because Veozah is not yet routinely stocked in Oman pharmacies, your physician may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Veozah is an oral once-daily selective NK3R antagonist that modulates the hypothalamic kisspeptin/neurokinin-B/dynorphin (KNDy) neuron pathway implicated in hot flashes after oestrogen decline. The manufacturer is Astellas Pharma. Dosing is 45 mg orally once daily. Eligibility rests on a clinical diagnosis of moderate-to-severe vasomotor symptoms of menopause where hormone therapy is contraindicated, not tolerated, or declined by the patient. The label requires baseline liver function testing, with periodic LFT monitoring monthly for the first three months and then as clinically indicated. Your physician confirms the indication, excludes patients with known liver disease or transaminase elevations, and reviews concomitant medications for CYP1A2-related interactions per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Veozah legally importable into Oman?
Yes, through Oman Ministry of Health and Prevention (MOHAP) named-patient import framework, with parallel coordination through the Department of Health Abu Dhabi or Dubai Health Authority where the treating physician is respectively licensed.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility, and (d) the importing party documents chain of custody. For women with vasomotor symptoms who cannot or prefer not to use hormone therapy, the clinical rationale for a first-in-class non-hormonal agent is straightforward to articulate.
How the pathway works, step by step
- Consultation with your treating physician. Confirmation of moderate-to-severe vasomotor symptoms, review of hormone-therapy suitability and patient preference, baseline liver function testing, and a written clinical rationale.
- Treatment-centre identification. A Oman gynaecology, endocrinology, or internal-medicine service that can arrange monthly LFT monitoring for the first three months accepts the case.
- MOHAP named-patient application. Your physician or the hospital's importing pharmacy files the application including prescription, clinical rationale, baseline LFT confirmation, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Stable shipment. Veozah is an oral tablet with standard storage requirements and ships with chain-of-custody documentation end to end.
- Arrival and initiation. Your physician starts therapy at 45 mg once daily and arranges the monthly LFT schedule. Reserve Meds coordinates re-supply ahead of bottle depletion.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming moderate-to-severe vasomotor symptoms of menopause, the reason hormone therapy is not being used, baseline liver-function status, and Veozah as the indicated therapy
- Verification of their Oman medical licence (MOHAP, DOH Abu Dhabi, or DHA)
- A current prescription naming the product, 45 mg once-daily dosing, and the planned schedule
- Patient identifier (anonymised reference preferred)
- Planned monitoring cadence (baseline plus monthly LFTs for three months, then as indicated)
Reserve Meds provides a physician documentation kit bundling the templates MOHAP reviewers expect to see for first-in-class oral therapies under named-patient import.
Costs and timing
Veozah's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 600-700. Logistics, MOHAP documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake, with a drug-only reference figure separated from service charges.
Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete MOHAP application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: menopause care in the Gulf region is increasingly addressed through gynaecology and women's-health clinics across Abu Dhabi and Dubai. Our concierge team coordinates re-supply and LFT scheduling in English or Arabic as you prefer, and handles correspondence discreetly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Veozah specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for MOHAP review, including LFT-baseline attestation templates.
- Logistics. Shipment coordination and chain-of-custody.
- Concierge case lead. A named point of contact throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Oman? Yes, when executed through the MOHAP named-patient framework with appropriate documentation. See our trust and compliance page.
Is Veozah a hormone? No. Veozah is a non-hormonal NK3R antagonist that acts on a hypothalamic pathway involved in hot flashes. It does not contain oestrogen or progesterone.
Why the monthly liver tests? Labeling reflects observed transaminase elevations in the clinical programme. The monthly LFT schedule for the first three months is a safety-monitoring requirement, not a suggestion. Your physician manages the cadence and any dose-interruption decisions.
What about drug interactions? Veozah is metabolised through CYP1A2 and strong or moderate CYP1A2 inhibitors are contraindicated or require caution. Your physician reviews your full medication list before prescribing.
Will private insurance cover this? Cash-pay is the default. Some Oman private insurers may reimburse named-patient imports for non-hormonal menopause therapies on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Veozah coordination in Oman, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-24.